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 Introduction 
 In the early 1940s, Gibson and Medawar  [1]  provided 
the first experimental evidence that homograft tissue re-
jection is an immune-mediated process. Based on this 
landmark collaboration, the need for immune suppres-
sion following organ transplantation was firmly estab-
lished and the era of immunomodulatory drug therapy 
was launched. Today, treatment with immunosuppressive 
agents has evolved into sophisticated regimes with opti-
mized pharmacokinetics and pharmacodynamics to min-
imize the chances of allograft rejection. Nevertheless, im-
munosuppressive therapy is a double-edged sword that 
puts the host at risk for a multitude of infectious, neoplas-
tic and vascular diseases, including posttransplant lym-
phoproliferative disorder (PTLD). Systemic PTLD can 
display morphological diversity, often resembling diffuse 
large B cell lymphoma, whereas isolated central nervous 
system (CNS) PTLD is usually monomorphic  [2] . Rarely, 
T cell PTLD is reported that is negative for Epstein-Barr 
virus (EBV) and behaves even more aggressively  [3] . It 
typically develops later than B cell PTLD, and patients are 
less likely to respond to a reduction of immunosuppres-
sive drugs  [3] . Until recently, PTLD has been considered 
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a rare disease. Because of the upward trend of organ trans-
plantation over the last 2 decades and the attendant im-
munosuppression-associated complications, PTLD is 
emerging as an increasingly important clinical entity. Still 
today, evidence-based treatment protocols are lacking 
and there is still no consensus regarding therapeutic regi-
mens  [4, 5] . In many transplant centers, weekly EBV-
DNA analysis via polymerase chain reaction is carried out 
to monitor the viral load and facilitate preemptive therapy 
with either reduction in the dose of immunosuppressive 
agents or anti-CD20 immunotherapy. Currently, innova-
tive triple-drug regimens are favored because of their dual 
antiproliferative and immunosuppressive properties  [5] . 
Our review focuses on the current literature on PTLD 
with the primary focus on isolated CNS manifestations. 
The clinicopathologic findings of this subgroup of PTLD 
have not yet been rigorously described and little experi-
mental data are available to explain the pathogenetic basis 
for its distinctive features. What has emerged from the 
existing literature is that primary CNS PTLD is distinctly 
more aggressive than its systemic counterpart  [6] . 
 Epidemiology 
 In 1968, Doak et al.  [7] published the first case-report 
of systemic lymphoproliferative disorder following renal 
transplantation, only a few years after the introduction of 
immunosuppressive therapy for transplant recipients  [8] . 
Shortly thereafter, Schneck and Penn  [9]  documented the 
first isolated case of cerebral PTLD following kidney 
transplantation. Subsequently, there has been a consider-
able increase in the annual incidence of PTLD, ranging 
from 1 to 10% depending on the organ transplanted  [10] . 
A study by Walker et al.  [11] reported the PTLD in 6.2% 
of patients after lung transplantation, in 5.2% after kidney 
and pancreas transplantation, in 2.0% after heart trans-
plantation and in 1.4% after liver transplantation. The 
difference in the frequency of PTLD among these groups 
has been attributed to the organ-specific immunosup-
pressive regimens. 
 Primary CNS PTLD has been observed in 5–15%
of all PTLD cases  [6] , much more frequent than CNS 
presentations in patients with de novo non-Hodgkin 
lymphoma. Whereas the highest incidence of systemic 
PTLD occurs within the first year after transplantation, 
with a median onset of 6 months  [6] , isolated CNS PTLD 
tends to appear much later. In a recent study on CNS 
PTLD, Castellano-Sanchez et al.  [6] reported onset la-
tencies ranging from 3 to 131 months (mean, 31 months) 
after transplantation. The general incidence of PTLD 
has increased dramatically due to several reasons, with 
the increase in transplantations being for the most ob-
vious explanation, followed by the considerably longer 
survival of transplant patients. In addition, the develop-
ment of highly potent immunosuppressive drugs ap-
pears to play a significant role in the rise of PTLD. Of 
particular relevance to the risk of developing PTLD is 
the total amount of immunosuppression over time in 
addition to the individual drug selection. Apart from 
dosage, certain combinations of medications, such as
tacrolimus and OKT3, have been reported to substan-
tially potentiate the risk of PTLD  [12] . Moreover, there 
is a 4-fold higher incidence of developing PTLD in chil-
dren compared to adults  [13] . This is commonly ex-
plained by EBV seronegativity in the pediatric popula-
tion before transplantation compared to the adult popu-
lation, where 90% are considered to carry a latent EBV 
infection. Thus the seronegative pediatric patients ac-
quire the virus with the transplanted organ, which seems 
to enhance the likelihood of developing PTLD  [13] ; 
which organ is transplanted is also a factor  [11] . Besides 
the EBV status of the host, allograft type and age are
additional variables implicated in the development of 
PTLD. The type and dosage of the immunotherapy re-
gime, multiorgan transplantation, concurrent human 
cytomegalovirus, hepatitis C infection and specific cyto-
kines are other factors that modulate EBV replication 
 [14, 15] . Also associated with a higher PTLD risk are the 
presence of a pretransplant malignancy, white race, 
male sex, therapy with calcineurin inhibitors, monoclo-
nal antibodies such as anti-CD3 (OKT3) and antithy-
mocyte globulin, tacrolimus and cyclosporine  [15] .
 Pathogenesis and Pathobiology 
 As noted, the vast majority (80%) of CNS PTLD cases 
are associated with EBV, also called  human herpesvirus 4 
(HHV-4), a double-stranded DNA virus of the γ-herpes-
virus family. In early-onset CNS PTLD, almost 100% of 
cases arise in the setting of EBV infection, latent, acute or 
acquired from the allograft. Two distinct stages are rec-
ognized in EBV infection: the lytic phase, characterized 
by active viral replication and the expression of all EBV 
proteins, which may lead to cell death and release of viri-
ons. During the latency phase, B cells are infected via their 
CD21 receptor and persist in the cell without lysis  [16, 
17] . In EBV-associated PTLD, EBV early RNA, EBV la-
tent membrane protein and EBV DNA are present  [18–
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20] . The underlying molecular pathogenesis is based on 
an uncontrolled proliferation of EBV-infected B cells af-
ter immunosuppressive therapy. Active EBV infection is 
usually acquired during childhood or adolescence, and 
eventually enters a latency phase, with viral DNA persist-
ing as a so-called episome in the nuclei of B lymphocytes 
 [21] . EBV encodes a series of proteins including the
EBV nuclear antigens, EBNA1 (DNA-binding nuclear 
phosphoprotein), EBNA2 (transcriptional coactivator), 
EBNA3A-C, EBNA-LP and the latent membrane protein 
LMP1, LMP2A and LMP2B. EBV-encoded nontransla-
tional RNAs are then transcribed  [20–22] and infected B 
cells differentiate into memory cells and EBV inclusions 
remain, with most of the infected cells cleared by cyto-
toxic T cells. Immunosuppressive therapy following 
transplantation unleashes a chain of events leading to de-
creased T cell functions, uncontrolled viral replication, 
expansion of EBV-infected B cells, EBV oncogene expres-
sion, proliferation and, ultimately, malignant transfor-
mation. Other molecular factors reported to abet the de-
velopment of PTLD are microsatellite instability, DNA 
hypermethylation and somatic mutations of proto-onco-
genes as well as molecular alterations of BCL-6, TP53 and 
c-MYC genes  [17] . The BCL-6 gene product is a tran-
scriptional repressor  [23, 24] , with rearrangement rarely 
seen in PTLD; however, somatic hypermutations are doc-
umented in several cases  [25] . The TP53 gene encodes a 
tumor suppressor and has been reported to be deleted in 
a small proportion of monomorphic PTLD  [26] . Addi-
tional evidence suggests that deregulation of the proto-
oncogene c-MYC, located on chromosome 8q24, is a fre-
quent target of chromosomal breaks that contribute to 
early pathomechanisms in the development of PTLD 
 [27] . Deregulation of c-MYC is regarded as a pivotal 
event in the pathogenesis of PTLD. c-MYC directly con-
trols DNA replication and plays a major role in regulating 
B cell proliferation  [28] . It has also been reported that c-
MYC-CD19 gene expression synergizes to trigger B cell 
transformation and lymphoma progression  [29] . Based 
on the induction of hyperphosphorylation, c-MYC is sta-
bilized and regulates a genetic pathway governed by cy-
clin D2 overexpression that enhances lymphomagenesis. 
Accordingly, agents that block the amplification of CD19 
(Src-family kinase) or inhibit Ras-ERK activity might im-
prove existing antilymphoproliferative therapies  [29] . 
Experiments have demonstrated that the oncogenes 
EBNA1 and LMP1 play a major role in the transforma-
tion of replicative EBV into oncogenic EBV in fibroblasts 
 [30] . LMP1 is considered to represent one of the major 
transforming factors of EBV. As an integral membrane 
protein expressed on the surface of infected B lympho-
cytes, LMP1 mimics CD40 receptors involved in the pro-
liferation and survival signaling in B cells  [31] . This is 
achieved by binding the cytoplasmic signal transduction 
molecule TRAF (TNF receptor-associated factors), which 
activates certain cellular signaling pathways (NF-κB, 
JNK1, AP1, Jak3/STAT and others). These signaling cas-
cades lead to enhanced expression of the antiapoptotic 
factors BCL-2 and A20, c-MYC and B cell adhesion mol-
ecules  [32] . Furthermore, transgenic mice expressing 
LMP1 are known to develop lymphomas after the upreg-
ulation of BCL-2 and A20 gene  [33] . However, given the 
large number of organ recipients and the fact that only a 
small percentage of patients who are seropositive for EBV 
develop PTLD, it is apparent that there are also other fac-
tors which contribute to the pathogenesis of monoclonal 
B cell proliferation. Epigenetic modifications of tumor 
suppressor and oncogenes represent further candidates 
discussed in the pathogenesis of PTLD. Among the epi-
genetic factors implicated in PTLD are the hypermethyl-
ation of serine-threonine kinase DAP-k, which is in-
volved in apoptotic signaling and the DNA repair gene 
O 6 -methylguanine-DNA methyl-transferase and is re-
ported to be methylated in 75% of polymorphic PTLD 
and in 93% of monomorphic PTLD  [27, 34] . Further 
genes known to be hypermethylated in PTLD are tumor 
suppressor genes P73 and P16 and the SHP1 gene, whose 
gene products inhibit the JAKs/STATs pathway and 
thereby slow B lymphocyte proliferation  [27, 35, 36] . In 
addition to the frequent association with EBV infection, 
PTLD shares other features common to immunodefi-
ciency-related lymphomas. The molecular pathogenesis 
and underlying cause of EBV seronegative PTLD are still 
unclear, with other viral agents being considered. Epide-
miological studies point to hepatitis C virus and simian 
virus as playing a possible role  [14, 15, 27] . Of interest, 
 human herpesvirus 8 (HHV-8) gene products possess ho-
mologies to human genes involved in antiapoptotic sig-
naling, cell proliferation and angiogenesis  [37] . 
 Clinical Manifestations and Diagnostic Aspects 
 Patients with CNS PTLD present with a multitude
of nonspecific clinical symptoms mostly related to the 
anatomical location of the lesions. For example, the
spectrum includes seizures, neuropsychiatric and focal 
symptoms. Other common clinical signs are attributed 
to increased intracranial pressure, including headache, 
nausea, vomiting, drowsiness and visual problems. In 
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contrast to other lymphoid malignancies, fever and oth-
er constitutional symptoms are uncommon in cerebral 
PTLD  [38] .
 Imaging 
 For the most part, the neuroradiographic features of 
PTLD are similar to those seen in immunocompromised 
individuals with primary CNS lymphoma. The most im-
portant radiological differential diagnosis in the post-
transplant setting, which can show overlapping imaging 
features, is a CNS infection. In a study by Castellano-San-
chez et al.  [6] , 10 of 12 CNS PTLD patients presented with 
multiple, contrast-enhancing, intra-axial lesions with ex-
tensive edema and marked expansion of the perivascular 
spaces. Moreover, multicentric lesions are more frequent 
in CNS PTLD than in other primary CNS lymphomas. 
Specifically, these lesions characteristically appear in the 
deeper supratentorial structures, periventricular region, 
and less frequently in the cerebellum and brainstem. Man-
ifestations in the spinal cord and leptomeninges have been 
rarely reported  [39] . In the cranial MRI scan, PTLD mass-
es appear hypointense to isointense on T1-weighted im-
ages. Areas of hyperintensity are thought to reflect the de-
gree of intratumoral hemorrhage. Hypercellularity is re-
flected by hypointensity in T2-weighted images, whereas 
tumor necrosis leads to focal hyperintensities. The more 
diffuse distribution of both signals is sometimes helpful in 
distinguishing a lymphoproliferative disorders from an 
abscess, because abscess fluid typically shows a central re-
gion of hyperintensity in the immunosuppressed brain. 
Contrast enhancement may be homogeneous; however, 
unlike CNS lymphoma, ring enhancement is seen in most 
a b
c d
e f
 Fig. 1. Histopathological features of EBV-
associated monomorphic B cell PTLD.  a ,
 b A diffuse infiltrate of transformed cells, 
partly with plasmacytic differentiation, in-
cluding immunoblasts. The tumor has a 
high proliferation rate (MIB-1) approach-
ing 80% ( c ) and abundant EBV positivity 
( d ). Numerous CD10-positive ( e ) and 
CD79a-positive immunoblasts ( f ) are de-
tectable in a typical perivascular arrange-
ment. 
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abscesses due to the presence of necrosis. Progressive mul-
tifocal leukoencephalopathy, another disorder seen in im-
munodeficient patients, is associated with only minimal 
or absent contrast enhancement. Besides toxoplasma en-
cephalitis, fungal and viral infections have to be taken into 
consideration  [40] . Even though all imaging features are 
nonspecific, when discovered in transplant recipients, the 
possibility of CNS PTLD has to be evaluated. 
 Histopathological Diagnosis and Classification 
 According to the World Health Organization (WHO) 
2008 classification of lymphoid neoplasms  [41] , PTLD is 
defined as ‘any lymphoid or plasmacytoid proliferation 
that develops in immunosuppressed recipients of solid or-
gan, bone marrow, or stem cell allografts’. Three main 
pathological subsets/stages are recognized: early, polymor-
phic and monomorphic lesions (see  table 1 ), which will be 
detailed below. According to their occurrence, PTLD is 
further categorized as either early-onset (within 1 year of 
the transplantation) or late-onset (>1 year). EBV positivity 
is not required for the diagnosis of PTLD. Common char-
acteristics encompass late onset and poorer response to 
therapy  [3] . In addition, a less frequent nongerminal center 
phenotype with BCL-6 expression and negative MUM-1/
IRF4 has been reported in EBV-negative examples  [42] . 
 Histopathology and Immunoprofile of PTLD 
 Early Lesions  
 Early lesions resemble reactive lymphoplasmacytic 
proliferations in immunocompetent hosts and lack de-
struction of the underlying tissue. These lesions include 
reactive plasmacytic hyperplasia and infectious mono-
Table 1. Categories of PTLD (WHO 2008) 
1. Early lesions
a Reactive plasmacytic hyperplasia
b Infectious mononucleosis-like lesions
2. Polymorphic PTLD
3. Monomorphic PTLD
B cell neoplasms
a Diffuse large B cell lymphoma
b Burkitt’s lymphoma
c Plasma cell myeloma
d Plasmacytoma-like lesions
e Others
T cell neoplasms
a Peripheral T cell lymphoma not otherwise specified
b Hepatosplenic T cell lymphoma
c Others
4. Classical Hodgkin’s lymphoma-type and Hodgkin’s lympho-
ma-like PTLD
a b
c d
 Fig. 2. Common immune signal expression 
pattern in monomorphic B cell PTLD.
 a Perivascular accumulation of CD20-pos-
itive B cells. The tissue displays partial ex-
pression of CD138 (syndecan-1)-positive 
plasmacytoid differentiated blasts ( b ). Fo-
cal BCL-2 expression mainly in immuno-
blasts ( c ) and sparsely distributed BCL-6 
( d ) immunopositivity is seen. 
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Table 2.  Entity-specific features in the differential diagnosis of posttransplant lymphoproliferations
Features CNS PTLD Primary CNS lymphoma Other lesions of the immunosuppressed brain
Clinical features
Age all ages, 1–80 years, median 43.4 years 
[6]
between the ages of 45 and 70 years,
median 60 years [51]
all ages, more common in elderly, often no 
convincing inflammatory/septic symptoms
Manifestation symptoms and signs of raised intra-
cranial pressure, focal neurological 
disorders (75% [2]) and seizures
focal deficits, neuropsychiatric signs, 
symptoms and signs of raised intracranial 
pressure, seizures, ocular symptoms
variable, from none to severe, depending on 
localization
symptomatic only in immunocompromised 
patients
Latency 3–131 months (mean 31 months) [6] variable variable, some remain latent infections
Cofactors immunosuppression after transplan-
tation
congenital, HIV [49] HIV, immunosuppression
Radiological features
Lesion multiple >> single lesions [2, 6] 65% solitary [49] scattered multifocal, edema and smaller
(toxoplasmosis)
single thin capsule (abscess)
incomplete, diffuse (demyelination)
multiple lesions in cortex (PML)
Enhancement heterogeneous contrast enhancement 
[2, 6]
homogeneous contrast enhancement, ring 
enhancement reported in HIV patients [49]
thick and nodular (neoplasm)
thin and regular (abscess)
incomplete ring (demyelination)
central targetoid, (toxoplasmosis)
none (PML), solid or ring-enhanced mass (TBC)
Localization 81% cerebral hemisphere
(cortex/white matter, basal ganglia, 
corpus callosum), 15% brainstem, 4% 
cerebellum, spinal cord involvement 
rare [6]
33% cerebral hemisphere, 16% thalamus/
basal ganglia, 14% corpus callosum, 12% 
periventricular region, 9% cerebellum, 
spinal cord involvement rare [49]
basal ganglia, often bilateral, and corticomedul-
lary junction (toxoplasmosis)
larger lesions (Aspergillus)
subcortical hemisphere white matter (PML)
frontoparietal and basal ganglia (TBC)
Edema extensive peritumoral edema com-
mon [6]
extensive peritumoral edema common [49] variable
mostly present (toxoplasmosis, abscess)
absent (PML)
Histopathological and molecular features
Infiltrate large, transformed cells with large, 
irregular nuclei, prominent nucleoli 
[6]
90–95% of primary CNS lymphomas are 
diffuse, large B cell lymphomas: mostly
large B cell type, immunoblasts and 
centroblasts [49, 50]
discrete multiple necrotizing lesions,
(toxoplasmosis)
demyelination, macrophages, viral inclusions, 
lymphocytic inflammation (PML)
surrounding epithelioid histiocytes, lymphocytes, 
plasma cells, multinucleated giant cells
(Langerhans type), plasma cells (TBC)
Growth pattern perivascular distribution, concentric 
laminar growth pattern, transmural 
invasion, sheet-like growth [6]
characteristic lymphoid clustering around 
small cerebral vessels [49]
multiple small cystic lesions, in periphery of 
necrotic areas, near blood vessel (toxoplasmosis)
Immune profile CD19+, CD20+, CD79a, CD45+
Germinal center type
(CD10±, BCL-6+, IRF4/MUM1–)
or nongerminal center type
(CD10–, BCL-6±, IRF4/MUM1+, 
CD138±)
pan-B cell markers (CD20, CD19, CD22, 
CD79a), markers of germinal center B cells 
(BCL-6; 60–80% of cases) and markers of 
late germinal center B cells (IRF4/MUM1; 
90%)
Rarely positive for CD10 (<10%) [50]
CD3+ (T cells), κ and λ light chains
(plasma cells), CD45+, CD15+ and CD30+ 
(large dysplastic cells)
toxoplasmosis +
SV-40+ (JC-virus, PML)
Grocott+ (Aspergillus)
Ziehl-Neelsen stain+ (Mycobacterium)
Streptococcus sp.+ (abscess)
Mitotic activity/MIB-1 increased [1] increased [50] not increased
Necrosis very common [2, 6] common variable
central caseation necrosis (TBC)
EBV/other 
pathogens
80% of all PTLD are positive for EBV
most CNS cases are EBV+ mPTLD [2, 
17]/HHV-8, simian virus 40, hepatitis 
C virus [17]
negative for EBV [50] negative for EBV
Toxoplasma gondii
JC-virus
Aspergillus fumigatus/flavus, Staphylococcus
Gene alterations cMYC, BCL-6, TP53 [17] CD95, cMYC13, PAX5, PIM1, PRDM114 
and TTF [50]
discussed
PML = Progressive multifocal leukoencephalopathy; TBC = tuberculosis.
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nucleosis-like PTLD which typically presents early after 
transplantation, usually appearing in the tonsils and 
lymph nodes  [41] . 
 Polymorphic PTLD 
 The hallmark of polymorphic PTLD is the presence of 
a mixed population of lymphoid and plasma cells. These 
tissue-destructive lymphoplasmacytic proliferations do 
not fulfill the criteria for a typical lymphoma as tradition-
ally seen in immunocompetent patients. They show ex-
tensive cellular and maturational-stage polymorphism 
and the characteristic immunoprofile comprising vari-
ably sized B cell clones admixed with heterogeneous T 
cells. The infiltrates show an angiocentric localization 
and necrosis is seen in one third of the cases.
 Monomorphic PTLD 
 Monomorphic PTLD (mPTLD) is defined as lesions 
containing numerous transformed lymphoid cells at one 
single maturational stage (see fig. 1). These may still show 
minimal pleomorphism and plasmacytic differentiation. 
The immune profile (see fig. 2) may either be that of a ger-
minal center type (CD10±, BCL-6+ and IRF4/MUM1–) or 
nongerminal center (CD10–, BCL-6±, IRF4/MUM1+ and 
CD138±)  [42] . 
 The cardinal features of cerebral mPTLD are abundant 
aggregates of large, neoplastic lymphoid cells, harboring 
huge irregularly shaped nuclei with prominent nucleoli. 
These immunoblastic-like tumor cells are arranged in an 
angiocentric pattern with layers of neoplastic cells sepa-
rated by concentric rings of reticulin fibers. A variable 
population of nonneoplastic T lymphocytes that diffusely 
infiltrate brain parenchyma is consistently present. The 
neoplastic B cells express CD19, CD20 and typically show 
immunopositivity for CD45 and EBV. Mitotic figures are 
common and, not surprisingly, the MIB-1 (Ki67) prolif-
eration index is high. Monomorphic T cell PTLD in the 
CNS is extremely rare. Most reported cases share similar 
histopathological features that resemble systemic T cell 
lymphomas with infiltrates of small, monomorphic lym-
phocytes. 
 Of special mention, T cell PTLD appears much later 
than other PTLD types and two thirds of these not associ-
ated with EBV seropositivity  [43] . Histologically, these 
entities often show necrosis and abundant, cytologically 
atypical lymphoid cells accompanied by reactive features 
that are sometimes indistinguishable from polymorphic 
PTLD. Immunohistochemistry with T cell markers is es-
sential to confirm the diagnosis.
 Classical Hodgkin Lymphoma-Type PTLD 
 To confirm the diagnosis of Hodgkin lymphoma-type 
PTLD, strict criteria must be fulfilled. These features in-
clude mixed cellularity, proliferations of small lympho-
cytes, plasma cells, histiocytes, eosinophils and Reed-
Sternberg cells. Immunohistochemically, Reed-Sternberg 
cells are CD15+, CD30+, PAX5+, CD20–, CD3– and 
CD45– and they are commonly surrounded by small T 
cell lymphocytes. 
 Differential Diagnosis 
 The recognition and accurate diagnosis of PTLD is of 
paramount importance for patient management. Pro-
curement of a representative biopsy is the essential first 
step for histopathological and immunochemical exami-
nation. The limited size of biopsy specimens, sampling 
heterogeneity and crush artifact pose additional challeng-
es to securing a firm diagnosis. Infectious disorders and 
other nonneoplastic lymphoproliferative disorders can 
sometimes mimic the histopathological features of PTLD 
(see table 2). As noted, diagnostic findings that argue for 
the diagnosis of PTLD are mass lesions composed of atyp-
ical lymphoid cells, numerous transformed cells, particu-
larly B cell-rich infiltrates, extensive serpiginous necrosis 
and a high proportion of plasma cells and EBV-positive 
cells. Even distinguishing CNS PTLD from nontrans-
plantation-asso ciated primary CNS lymphomas is clini-
cally relevant, as the prognosis and treatment strategies 
differ. Clearly, the clinical context defines the diagnostic 
considerations.
 Prognostic Factors for PTLD Progression 
 Similar to non-Hodgkin lymphomas, patient age, mul-
tifocal disease and poor general performance (Karnovsky 
score) are associated with poor prognosis  [44] . The rare 
T cell variant is known to have a worse prognosis  [45] . 
Given the rarity of CNS PTLD patients, reliable informa-
tion on prognostic factors is still missing.
 Treatment Modalities  
 Despite the fact that PTLD is now a recognized com-
plication of transplantation, no standard protocols exist 
for its prevention or treatment. Surgical resection is of no 
benefit and radiation therapy plays only a limited role
in preventing cerebral herniation. Chemotherapy is the 
therapeutic mainstay and several new approaches have 
emerged over the last decade that are described in greater 
depth elsewhere  [46] . Briefly, the therapeutic goal is to 
reduce the tumor burden with the lowest possible dose of 
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